Compositions and methods for treating CNS disorders

Details Compositions and methods for treating CNS disorders Compositions and methods for treating CNS disorders

2005-11-10

2009-10-06

Andres, Janet L. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S114000

Reexamination Certificate

active

07598265

ABSTRACT:
The invention generally relates to thienopyridinone 5-HT4receptor modulators, and in particular the use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with serotonin action, such as in treating Alzheimer's disease, cognition disorders, depression, and anxiety.

REFERENCES:
patent: 3069412 (1962-12-01), Roberts et al.
patent: 3658807 (1972-04-01), Schmidt et al.
patent: 4146716 (1979-03-01), Cox et al.
patent: 4316020 (1982-02-01), Reissenweber et al.
patent: 5155155 (1992-10-01), Jurlaro et al.
patent: 5219864 (1993-06-01), Suzuki et al.
patent: 5227387 (1993-07-01), Dreikorn et al.
patent: 5236917 (1993-08-01), Dunlap et al.
patent: 5371074 (1994-12-01), Dunlap et al.
patent: 5378679 (1995-01-01), Nuebling et al.
patent: 5571815 (1996-11-01), Schaper et al.
patent: 5591751 (1997-01-01), Fujioka et al.
patent: 5593943 (1997-01-01), Nuebling et al.
patent: 5596012 (1997-01-01), Dunlap et al.
patent: 5650422 (1997-07-01), Dunlap et al.
patent: 5753673 (1998-05-01), Ohuchi et al.
patent: 5798451 (1998-08-01), von Deyn et al.
patent: 5874432 (1999-02-01), Dunlap et al.
patent: 5972841 (1999-10-01), von Deyn et al.
patent: 6103903 (2000-08-01), Cai et al.
patent: 6159962 (2000-12-01), Steiner et al.
patent: 6187788 (2001-02-01), Furuya et al.
patent: 6222034 (2001-04-01), Steiner et al.
patent: 6232320 (2001-05-01), Stewart et al.
patent: 6300333 (2001-10-01), Schaper et al.
patent: 6340759 (2002-01-01), Ueno et al.
patent: 6596727 (2003-07-01), Schaper et al.
patent: 6924283 (2005-08-01), Thorarensen
patent: 7030240 (2006-04-01), Dhanoa et al.
patent: 7119205 (2006-10-01), Iyengar et al.
patent: 7153858 (2006-12-01), Dhanoa et al.
patent: 7407966 (2008-08-01), Dhanoa et al.
patent: 2002/0028782 (2002-03-01), Castelhano et al.
patent: 2004/0138238 (2004-07-01), Dhanoa et al.
patent: 2005/0049243 (2005-03-01), Ballard et al.
patent: 2005/0065176 (2005-03-01), Field et al.
patent: 2005/0137142 (2005-06-01), Schulz et al.
patent: 2005/0222175 (2005-10-01), Dhanoa et al.
patent: 2005/0222176 (2005-10-01), Dhanoa et al.
patent: 2006/0084805 (2006-04-01), Dhanoa et al.
patent: 2006/0084806 (2006-04-01), Sridharan et al.
patent: 2006/0205737 (2006-09-01), Becker et al.
patent: 2007/0004742 (2007-01-01), Dhanoa et al.
patent: 2007/0173487 (2007-07-01), Saha et al.
patent: 0447891 (1991-09-01), None
patent: 0503844 (1992-09-01), None
patent: 0503844 (1992-09-01), None
patent: 0505058 (1992-09-01), None
patent: 0505058 (1992-09-01), None
patent: 0 710 662 (1996-05-01), None
patent: 1 018 513 (2000-07-01), None
patent: 1 018 513 (2000-07-01), None
patent: 0 710 662 (2001-04-01), None
patent: 1229025 (2002-08-01), None
patent: 1325921 (2003-07-01), None
patent: 1325921 (2003-07-01), None
patent: 1 018 513 (2006-02-01), None
patent: 2295387 (1996-05-01), None
patent: 11 130777 (1999-05-01), None
patent: WO 94/12176 (1994-06-01), None
patent: WO 94/22871 (1994-10-01), None
patent: WO 00/64441 (2000-11-01), None
patent: WO 01/14333 (2001-03-01), None
patent: WO 01/25218 (2001-04-01), None
patent: WO 02/102797 (2002-12-01), None
patent: WO 2004/014850 (2004-02-01), None
patent: WO 2004/017950 (2004-03-01), None
patent: WO 2004/030629 (2004-04-01), None
patent: WO 2004/034963 (2004-04-01), None
patent: WO 2004/089312 (2004-10-01), None
patent: WO 2005/121151 (2005-12-01), None
patent: WO2005/121151 (2005-12-01), None
patent: WO 2006/041985 (2006-04-01), None
patent: WO 2007/058805 (2007-05-01), None
patent: WO 2008/002539 (2008-01-01), None
patent: WO 2008/045558 (2008-04-01), None
patent: WO 2008/060632 (2008-05-01), None
Buchstaller, H.P., et al., “Thieno[2,3-b]pyridinones as Antagonists on the Glycine Site of the N-methyl-D-aspartate Receptor-Binding Studies, Molecular Modelling and Structure-Activity-Relationships”, Scientia Pharmazeutica, 68, 3-14 (2000).
Lamirault, L., et al., “Combined Treatment with Galanthaminium Bromide, a New Cholinesterase Inhibitor, and RS 67333, a Partial Agonist of 5-HT4 Receptors, Enhances Place and Object Recognition in Young Adult and Old Rats,” Progress in Neuro-Psychopharmacology & Biological Psychiatry 27 (2003) 185-195.
Moser, Paul C., et al., “SL65.0155, A Novel 5-Hydroxytryptamine4 Receptor Partial Agonist with Potent Cognition-Enhancing Properties,” The Journal of Pharmacology and Experimental Therapeutics, 302:731-741, 2002.
Science IP Search, Apr. 30, 2004.
Science IP Search, May 11, 2004.
Stachel, Hans-Dietrich, et al., “Derivatives of Oxalyldimalonic Acid,” 1995.
Suzuki, M., “Synthesis and Evaluation of Novel 2-Oxo-1,2-dihydro-3-Quinolinecarboxamide Derivatives as Potent and Selective Serotonin 5-HT4 Receptor Agonists,” Chem Pharm. Bull., 49(1) 29-39, 2001.
Buchheit et al.J. Med. Chem., 38(13):2326-2330 (1995).
Buchheit et al.J. Med. Chem., 38(13):2331-2338 (1995).
Kaumann, A.J.Naunyn-Schmiedeberg's Arch. Pharmacol., 342:619-622 (1990).
Moser et al.J. Pharmacol. Exp. Ther., 302(2):731-741 (2002).
Abenhaim et al. N. Engl. J. Med., 335(9):609-616 (1996).
Barker et al., Journal of Chemical Research, Synopses, 1985 (7) 214-15.
Brea et al. J. Med. Chem., 45:54-71 (2002).
Coppola et al., Journal of Organic Chemistry, 1976 (41) 825-831.
Database Caplus on STN, Accession No. 1999:783937, Castelhano et al., WO 99/62518 A1, Cadue Pharmaceuticals Corp. Dec. 9, 1999.
Database Caplus on STN, Accession No. 2000:806616 Horvath, et al., Neurogen Corporation. 6,147,085, Nov. 14, 2000.
Doggrell, Sheila A., Expert Opin. lnvestig. Drugs, 2003 (12) 805-823.
Farber et al. N. Engl. J. Med., 351(16):1655-1665 (2004).
Fishman Chest, 114(3):242S-247S (1998).
Fitzgerald et al. Mol. Pharmacol., 57:75-81 (2000).
Gordon W. Gribble, Sodium Borohydride in Carboxylic Acid Media: A Phenomenal Reduction System, Chemical Society Reviews, 1998 (27) 395-40.
Hutchins, R.O., et al., J. Org. Chem., 1977 (42) 82-91.
Hwang et al., Arch. of Pharm. Res., 2001, 24(4), 270-275.
International Search Report for PCT/US2003/23539 mailed Jul. 23, 2004.
International Search Report for PCT/US2004/09944 mailed Mar. 1, 2005.
International Search Report for PCT/US2005/035935 mailed May 12, 2006.
International Search Report for PCT/US2005/034862 mailed Jan. 24, 2006.
International Search Report for PCT/US2005/17121 mailed Apr. 4, 2006.
International Search Report for PCT/US2006/043140 mailed Aug. 16, 2007.
Jerry March in Advanced Organic Chemistry 4th Edition, 1992, by John Wiley & Sons: New York, pp. 378-383.
Kennett et al. Neuropharmacol., 36(2):233-239 (1997).
Kursar et al. Mol. Pharmacol., 46(2):227-234 (1994).
Kuryshev et at J. Pharmacol. Exp. Ther., 295(2):614-620 (2000).
Launay et al. Nat. Med., 8(10):1129-1135(2002).
MacLean Trends Pharmacol. Sci., 20(12):490-495 (1999).
Manivert et al. J. Biol. Chem., 277(19):17170-17178 (2002).
Marcos et al. Circ. Res., 94:1263-1270 (2004).
Nauser et al. Am. Fam. Physician, 63(9):1789-1798 (2001).
Nebigil et al. Proc. Natl. Acad. Sci. U.S.A., 97(6):2591-2596 (2000).
Poissonnet et al. Mini-Rev. Med. Chem., 4(3):325-330 (2004).
Recanatini, M., et al., “Acetylcholinesterase Inhibitors in the Context of Therapeutic Strategies to Combat Alzheimer's Disease,” Expert Opinion on Therapeutic Patents, Ashley Publications, GB, vol. 12, No. 12, 2002, 1853-1865.
Rich et al. Chest, 117(3):870-874 (2000).
Rothman et al. Circulation, 102:2836-2841 (2000).
Setola et al. Mol. Pharmacol., 63(6):1223-1229 (2003).
Takashi et al., Bioorganic & Medicinal Chemistry Letters, 2002 (12) 2427-2430.
Teoh et al., “Hypoxia Enhances 5-HT2B Receptor Response and Expression the Rat Pulmonary Artery”, Abstract only, International Conference of the American Thoracic Society, San Diego (May 24, 2005).
Ullmer et al. Br. J. Pharmacol., 117(6):1081-1088 (1996).
Witchel et al. FEBS Lett., 512(1-3):59-66 (2002).
Witchel et al. J. Clin. Psychopharmacol., 23(1):58-77 (2003).
Yamada et al. Eur. J. Pharmacol., 406(1):153-157 (2000).

Affiliated with

Also associated with

Rating

Compositions and methods for treating CNS disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for treating CNS disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating CNS disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4132477